!Kung & Rosemary,
Not to be cheerleader, but...8! Yes...you can do it...come on ABTI! <g>
Rosemary - On a more serious note, if you haven't followed a biotech through the whole PIII data, NDA, FDA cycle several times, I strongly recommend against playing options with anything more complicated than straight calls.
IMO, it looks like we'll move up from here (unless the shorts decide to cycle us again) as new money sees PIII data coming due. Conventionally, the stock should pop up from that uptrend on good news and then sag somewhat as profit-taking and the reality of the long path remaining to market hits home. Lately, however, there seems to have been a lot of "selling into the news," damping the pop in other biotechs. IMHO, the important thing to consider is what you consider the fair price of ABTI if successful data (using cold logic). If the price is there before the data, expect selling into the news; if it's significantly below, then IMO we may see a pop on good data.
For what it's worth,
biowa |
